Results 201 to 210 of about 74,736 (296)

Molecular profile of atypical Leydig cell tumours

Histopathology, Volume 88, Issue 3, Page 628-635, February 2026.
Copy number variations by themselves are not sufficient to discriminate between benign and potential malignant Leydig cell tumours (LCTs). Genomic instability was only detected in malignant and atypical cases, and not in any benign tumours. Currently, the presence of metastasis remains the only malignant criterion for LCTs.
Muhammad F.K. Choudhry, Diogo Caires, Yaser Gamallat, Asli Yilmaz, Fadi Brimo, Bob Argiropoulos, Tarek A. Bismar   +6 more
wiley   +1 more source

Case Report: Alpha-fetoprotein-producing urothelial carcinoma of the bladder. [PDF]

Front Oncol
Huang H, Ding Y, Fang Y, Xie K, Zhong C, Fan H, Zou X, Xie T.   +7 more
europepmc   +1 more source

T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Hepatocellular carcinoma (HCC), accounting for over 90% of primary liver cancers, remains a major global challenge for healthcare professionals. While immunotherapy has transformed the landscape of cancer treatment, its success is often limited by immune resistance, particularly through T cell exhaustion which remains a major barrier to ...
Kosar Nouri, Negar Asadollahei, Yasamin Haghir‐Sharif‐Zamini, Homeyra Seydi, Mahsa Salehi, Mehrnaz Mesdaghi, Mustapha Najimi, Massoud Vosough   +7 more
wiley   +1 more source

Clinical performance of GAAD score, alpha-fetoprotein, and PIVKA-II in diagnosing hepatocellular carcinoma in the Vietnamese cohort. [PDF]

Discov Oncol
Pham TTT, Ho DT, Nguyen TB, Phan HT.
europepmc   +1 more source

Studies on the activity of .ALPHA.-fetoprotein gene.

, 1981
Nam-Ho Choi, Tokuhiko Higashi
openalex   +2 more sources

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study

Liver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background/Aims Immune checkpoint inhibitors (ICIs) have transformed advanced HCC treatment. The benefit of sequential immunotherapy after prior ICI failure remains unclear. Given the expanded use of atezolizumab plus bevacizumab (Ate/Bev) over the past 5 years, we explored the real‐world outcomes of nivolumab plus ipilimumab (Nivo/Ipi) in ...
Jung Sun Kim, Jeffrey Wong, San‐Chi Chen, David Tai, Hannah Yang, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Chansik An, Su Jin Jang, Masatoshi Kudo, Ho Yeong Lim, Chan Kim, Thomas Yau, Hong Jae Chon   +15 more
wiley   +1 more source

Alpha-fetoprotein: A Multifaceted Player in Cancer Biology. [PDF]

Euroasian J Hepatogastroenterol
Ucdal M, Yazarkan Y, Sonmez G, Celtikci B, Balaban Y.   +4 more
europepmc   +1 more source

ALPHA-FETOPROTEIN

The Kurume Medical Journal, 1977
openaire   +2 more sources

Alpha fetoprotein antagonizes apoptosis induced by paclitaxel in hepatoma cells in vitro [PDF]

, 2016
Mingyue Zhu, Wei Li, Yan Lu, Dong Xu, Yi Chen, Bo Lin, Xieju Xie, Junli Guo, Mengsen Li   +8 more
openalex   +1 more source

Alpha-fetoprotein in chronic hepatitis C

Journal of the Formosan Medical Association, 2011
Ching-Sheng Hsu
doaj   +1 more source